Protocol Ledger

NCT03511664 · Phase III · COMPLETED

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Interventional Phase III clinical trial protocol NCT03511664 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-29 Enrollment: 861 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03511664
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)861 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03511664
Protocol FieldVerified Registry Value
NCT IdentifierNCT03511664
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment861 participants (ACTUAL)
Registered Start Date2018-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI